Celgene Corporation
http://www.celgene.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celgene Corporation
Takeda Moves Takhzyro Toward Dominant Position In Pediatric HAE
The company announced data from the Phase III SPRING study of Takhzyro in children aged 2-11; there is no approved long-term prophylactic therapy for children under 6.
Deal Watch: Iktos Doubles Its 2022 Alliance Tally In Agreements With Galapagos, Zealand
French AI-driven drug design firm will employ multiple technology platforms in latest tie-ups. Apellis looks to augment Empaveli-led portfolio in C3 complement R&D alliance with Affilogic.
Prevacid 24HR First OTC PPI With Skin Reaction Warning
Lansoprazole along with other OTC and Rx PPI ingredients were linked to a potential risk of acute generalized exanthematous pustulosis FDA in 2019 found a trend in adverse event reports.
Bayer Banks On Boston To Achieve Oncology Ambitions
The German major is investing heavily in cancer R&D and has opened the doors of a new facility in the biotech epicenter on the east coast of the US.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Abraxis BioScience, Inc.
- AbVitro, Inc.
- Acetylon Pharmaceuticals, Inc.
- Avila Therapeutics, Inc.
- Delinia, Inc.
- EngMab AG
- Gloucester Pharmaceuticals, Inc.
- Impact Biomedicines, Inc.
- Juno Therapeutics, Inc.
- Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
- JW Biotechnology (Shanghai) Co., Ltd
- Pharmion Corporation
- Quanticel Pharmaceuticals, Inc.
- Receptos, Inc.
- RedoxTherapies, Inc.
- X-BODY, Inc.